Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) according to Baseline BMI

被引：0
|
作者：
Kis, Janos T.
Seufert, Jochen
Haluzik, Martin
Vera, Carine
Tournay, Mathilde
Bonnemaire, Mireille
Freemantle, Nick
Guja, Cristian
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-786-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
786-P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naive People with Type 2 Diabetes: the ATOS Study
    Galstyan, Gagik R.
    Tirosh, Amir
    Vargas-Uricoechea, Hernando
    Mabunay, Maria Aileen
    Coudert, Mathieu
    Naqvi, Mubarak
    Pilorget, Valerie
    Khan, Niaz
    [J]. DIABETES THERAPY, 2022, 13 (06) : 1187 - 1202
  • [32] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIA
    Bogdanovic, M.
    Fournier, M.
    Vitezic, D.
    [J]. VALUE IN HEALTH, 2018, 21 : S131 - S132
  • [33] COST-UTILITY EVALUATION OF INSULIN GLARGINE (300 U/ML) VERSUS INSULIN GLARGINE (100 U/ML) AND INSULIN DEGLUDEC (100 U/ML) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SERBIA
    Mihajlovic, J.
    Bogdanovic, M.
    Foumier, M.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A481 - A481
  • [34] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA
    Bogdanovic, M.
    Mihajlovic, J.
    Fournier, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S133 - S133
  • [35] Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study
    Malik, Rayaz A.
    Hwu, Chii-Min
    Jammah, Anwar A.
    Arteaga-Diaz, Juan M.
    Djaballah, Khier
    Pilorget, Valerie
    Alvarez, Agustina
    Vera, Carine
    Vikulova, Olga
    [J]. DIABETES OBESITY & METABOLISM, 2024, 26 (07): : 2811 - 2819
  • [36] Glycaemic control in people with type 2 diabetes (T2D) switching from NPH to insulin glargine 300 U/mL (Gla-300): REALI pooled database
    Mueller-Wieland, D.
    Freemantle, N.
    Bonadonna, R.
    Mauquoi, C.
    Bigot, G.
    Bonnemaire, M.
    Gourdy, P.
    Mauricio, D.
    [J]. DIABETOLOGIA, 2022, 65 (SUPPL 1) : S333 - S334
  • [37] Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
    Kovatchev, Boris
    Meng, Zhaoling
    Cali, Anna M. G.
    Perfetti, Riccardo
    Breton, Marc D.
    [J]. DIABETES THERAPY, 2020, 11 (06) : 1293 - 1302
  • [38] Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
    Boris Kovatchev
    Zhaoling Meng
    Anna M. G. Cali
    Riccardo Perfetti
    Marc D. Breton
    [J]. Diabetes Therapy, 2020, 11 : 1293 - 1302
  • [39] Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves beta cell function in people with type 2 diabetes
    Ferrannini, E.
    Boss, A.
    Dex, T.
    Servera, S.
    Mari, A.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 261 - 262
  • [40] The effectiveness of insulin glargine 300 U/ml among type 2 diabetes patients: analysis of a real world data
    Cohen, C. Melzer
    Shalev, V.
    Chodick, G.
    [J]. DIABETOLOGIA, 2019, 62 : S436 - S437
12345